The prevention and control of the covid-19 epidemic has become normal. What is the progress of the on-site rapid detection of viral nucleic acid products? On July 29, the “Application and Promotion of Analytical Testing Technology and Products in the Detection of Covid-19 Virus” symposium sponsored by the Guangdong Provincial Department of Science and Technology was held in Guangzhou. Eight experts from scientific research institutions and enterprises shared the science and technology resistance. Practice and results of the "epidemic". Among them, the research and development of rapid detection products is one of the focuses of hot discussion on site.
Detection technology and products are the key to scientific prevention and control of infectious diseases, early detection, early reporting, and early diagnosis of epidemics, and effective control of the spread of infectious diseases. According to Gong Jianwen, the second-level inspector of the Provincial Department of Science and Technology, at present, the scientific research team of our province is working hard to develop nucleic acid rapid detection products to adapt to and meet the needs of the current situation.
The epidemic prevention and control is facing the challenge of imported cases from abroad. What role can rapid detection products play? "You can imagine the following scenario: With the help of rapid detection products, all passengers can be tested for nucleic acid on passenger plane flights, and the test results are already available when the passengers enter the customs, thereby helping precise prevention and control." Guangzhou Regenerative Medicine and Health Guangdong Province Experiment Song Yangzhou, deputy director of the clinical transformation department of the laboratory, said.
Songyangzhou said that the current nucleic acid detection of the COVID-19 virus in the laboratory takes a long time, generally more than 4 hours, and requires high requirements for the storage and transportation of samples and the technical level of the operators. The laboratory and Professor Songyangzhou’s team are committed to the development of "one-step" nucleic acid rapid detection kits and test card products suitable for primary diagnosis and treatment, on-site epidemic control, etc., to solve the existing detection schemes that rely on high-value instruments and professionals Operational problems.
With the help of a fully enclosed manual nucleic acid sample extraction device, on-site extraction operations can be performed, and the detection can be completed in about 30 minutes. From the perspective of technical requirements, ordinary technicians and even ordinary people in medical and health institutions can operate after simple training, laying the foundation for product application in communities, homes and other scenarios. "Songyangzhou said that in the future, rapid detection products can be directly applied at customs, airports and other entry and exit gates, basic hospitals, and communities. While ensuring the accuracy of detection, it greatly saves time and the cost of purchasing large instruments.
Songyangzhou revealed that the production preparations for related rapid test products are basically in place, but they still need to go through clinical trials, approvals, and mass production stages before they are marketed and put into use.
In fact, the research and development of detection products has always been the key direction of scientific research for epidemic prevention and control in Guangdong Province. According to Gong Jianwen, Guangdong has deployed 30 detection product research and development and established an infectious disease diagnostic reagent industry technology innovation alliance. As of July 28, Guangdong enterprises had produced more than 192 million servings, which not only met domestic demand, but also sold more than 105 million servings to more than 70 countries and regions around the world.
In addition to testing products, Guangdong enterprises also send testing equipment and technology to outside the province or even abroad. Yin Ye, CEO of Shenzhen Huada Gene Technology Co., Ltd., and Xie Jiangtao, vice president of Guangzhou Jinyu Medical Laboratory Group Co., Ltd., respectively introduced their respective companies' experiences in helping key areas for epidemic prevention and control.
This symposium is one of the series of seminars in the Guangzhou International Analytical Testing and Laboratory Equipment Exhibition and Technical Seminar ("CHINA LAB 2020"). It comes from universities, scientific research institutions, and hospitals in the field of analytical testing technology and product development and production. , More than 160 people from more than 100 companies attended the conference. The meeting also set up a special exhibition area for scientific research on epidemic prevention and control in Guangdong Province, focusing on the staged progress in scientific research on clinical treatment and drugs, vaccine research and development, detection technology and products, viral etiology, and epidemiology in Guangdong Province.
0 Comments